Skip to main content

Formulate

Find pharma jobs. Prep for interviews like no one else can.

Browse

Jobs Companies Drugs Indications Career Advisor About

Insider Intel

Intelligence Hub Therapeutic Areas Contribute Intro Network Salary Explorer For Employers Pricing

Legal

Privacy Policy Terms of Service About Our Crawler Content Removal Your Privacy Choices

© 2026 Formulate. Pharma Jobs with Drug Intelligence.

argenx Jobs | Formulate

Jobs
argenx

argenx Jobs

Belgium - Zwijnaarde

Biotechnology

argenx is a life sciences company focused on Antibody therapies.

77 open positions at argenx

View Full Profile

Filters:Immunology ×

Business Leader, Mid-Atlantic (Mid-Atlantic)

argenx

Posted 3w ago

United States - Field

$204K - $281K

Full-time

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

ImmunologyMID

H-1B · 1 FY23

Business Leader, Florida & Puerto Rico (North Florida)

argenx

Posted 3w ago

United States - Field

$204K - $281K

Full-time

Market Head, Midwest

argenx

Posted 3w ago

United States - Field

$236K - $325K

Full-time

Market Head, Rocky Plains

argenx

Posted 3w ago

United States - Field

$236K - $325K

Full-time

Market Head, Mid-Atlantic

argenx

Posted 3w ago

United States - Field

Full-time

Business Leader, Southeast (South Atlantic)

argenx

Posted 3w ago

United States - Field

$204K - $281K

Full-time

Business Leader, Florida & Puerto Rico (South Florida)

argenx

Posted 3w ago

United States - Field

$204K - $281K

Full-time

Business Leader, Great Lakes (Michigan)

argenx

Posted 3w ago

United States - Field

$204K - $281K

Full-time

Market Head, South Central

argenx

Posted 3w ago

United States - Field

$236K - $325K

Full-time

Manager Internal Controls

argenx

Posted 1mo ago

Gent, Belgium

Full-time

Trial Operations Excellence & Innovation Lead

argenx

Posted 1mo ago

Remote

Full-time

Franchise Clinical Operations Development Lead (CODL)

argenx

Posted 1mo ago

Remote

$268K - $369K

Full-time

Associate Director Regulatory CMC – Development

argenx

Posted 1mo ago

Gent, Belgium

Full-time

Program Director, Governance Forums

argenx

Posted 1mo ago

Remote

$212K - $292K

Full-time

Clinical Operations Development Lead

argenx

Posted 1mo ago

Remote

$212K - $292K

Full-time

DT AI Platform Lead

argenx

Posted 1mo ago

Gent, Belgium

Full-time

Head of Specialized Sourcing

argenx

Posted 2mo ago

Gent, Belgium

Full-time

Executive Assistant

argenx

Posted 2mo ago

Boston, MA, USA

$76K - $105K

Full-time

Legal Counsel, Clinical Development

argenx

Posted 2mo ago

Remote

Full-time

Associate Director, Medical Writing

argenx

Posted 2mo ago

Remote

$164K - $226K

Full-time

Previous
1
2
3

Company Overview

Active Jobs

84

Pipeline Programs

88

Drug Products

2

Clinical Trials

98

View Full Company Profile

Therapeutic Areas

Neurology Immunology Oncology

Links

Company Website Careers Page

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

ImmunologyMID

H-1B · 1 FY23

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

ImmunologyMID

H-1B · 1 FY23

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

ImmunologyMID

H-1B · 1 FY23

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

ImmunologyMID

H-1B · 1 FY23

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

ImmunologyMID

H-1B · 1 FY23

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

ImmunologyMID

H-1B · 1 FY23

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

ImmunologyMID

H-1B · 1 FY23

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

ImmunologyMID

H-1B · 1 FY23

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

ImmunologyMANAGER

H-1B · 1 FY23

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

RemoteImmunologySenior

H-1B · 1 FY23

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

RemoteClinical OperationsImmunologySenior

H-1B · 1 FY23

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

Regulatory AffairsImmunologyExecutive

H-1B · 1 FY23

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

RemoteImmunologyExecutive

H-1B · 1 FY23

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

RemoteClinical OperationsImmunologySenior

H-1B · 1 FY23

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

ImmunologySenior

H-1B · 1 FY23

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

ImmunologyExecutive

H-1B · 1 FY23

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

ImmunologyExecutive

H-1B · 1 FY23

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

RemoteClinical DevelopmentImmunologyMID

H-1B · 1 FY23

Related drug: VYVGART

Condition in scope: Neonatal Presentation (First 28 Days of Life)

RemoteMedical WritingImmunologyExecutive

H-1B · 1 FY23